Neurology devices market size in 2026 is estimated at USD 15.82 billion, growing from 2025 value of USD 15.10 billion with 2031 projections showing USD 20.02 billion, growing at 4.80% CAGR over 2026-2031. This report Segments the Industry Into by Type of Device (Neurostimulation Devices, Interventional Neurology Devices and More), by Application (Stroke Management, Chronic Pain & Movement Disorders and More), by End User (Hospitals, Ambulatory Surgery Centers and More) and Geography (North America, Europe, Asia-Pacific and More). The Market Forecasts are Provided in Terms of Value (USD).
Rehabilitation & wearable devices, posting a 5.18% CAGR, increasingly enable post-operative and chronic-disease monitoring at home. In-ear EEG wearables capture seizure precursors, reducing emergency admissions and widening recurring-service revenue. Competitive barriers here hinge on data-analytics IP rather than hardware, inviting tech entrants. Consequently, incumbent catheter and shunt suppliers diversify portfolios to hedge against slower growth in mature theatre-based products.
Asia-Pacific posts the quickest 6.92% CAGR, propelled by China’s BCI roadmap and Japan’s remote-care pilots. Government grants subsidise domestic flow-diverter manufacturing, reducing import reliance and bolstering local champions. India logs double-digit growth in detachable-coil sales as its ageing cohort expands, although affordability gaps persist.
Europe remains a steady contributor, emphasising clinical-value demonstration under Medical Device Regulation. Germany’s rising hydrocephalus incidence fuels shunt demand, whereas the United Kingdom pilots AI-triaged stroke pathways that may scale continent-wide. Meanwhile, Switzerland’s potential recognition of FDA approvals streamlines dual-market launches, benefiting US-centric manufacturers.
Global Neurology Devices Market Trends and Insights
Rising Prevalence of Neuro-vascular & Neuro-degenerative Disorders
Neurological conditions now affect 43% of the global population, expanding the addressable pool for therapeutic devices.. Stroke remains paramount: large-vessel occlusions represent up to 40% of ischemic cases and demand rapid thrombectomy solutions. Post-viral neurological sequelae following COVID-19 and other pathogens further elevate device utilization. Given these epidemiologic realities, the Neurology Devices market continues to prioritise high-efficacy interventions and scalable chronic-disease monitoring strategies.Technological Advances in Minimally Invasive & Image-Guided Devices
Fourth-generation aspiration catheters, steerable micro-catheters and 300 mT/m gradient MRI scanners shorten procedure time and elevate diagnostic precision. Real-time algorithms embedded in thrombectomy devices improve first-pass success and reduce downstream costs. Interplay of robotics, augmented reality and AI prompts faster learning curves for neurosurgeons, helping address workforce deficits. By raising clinical thresholds, technology upgrades consolidate share for R&D-intensive firms and reinforce entry barriers, affecting long-tail suppliers in the Neurology Devices industry.High Device & Procedure Cost Burden
Spinal cord stimulation implants cost USD 35,000-70,000, while revisions add USD 15,000-25,000, limiting penetration among under-insured cohorts Journal of Pain Research. Explant rates hover near 10% owing mainly to efficacy loss, raising total-cost-of-ownership anxieties. In India, detachable coils for aneurysm repair attract import duties of 10%, compounding affordability hurdles MD+DI. Such cost vectors slow adoption despite clinical need.Other drivers and restraints analyzed in the detailed report include:
- Expanding Healthcare Spend & Neuro-rehab Reimbursement Schemes
- Wearable EEG & At-Home Neuro-monitoring Creating New Outpatient Revenue
- Lengthy & Complex Regulatory Approval Cycles
Segment Analysis
Interventional systems captured 38.45% Neurology Devices market share in 2025 as mechanical thrombectomy and flow-diverter implants became standard of care for acute ischemic stroke. Data from the EXCELLENT registry showed final reperfusion rates of 94.5% with the EMBOTRAP retriever, reinforcing physician confidence. Neurodiagnostic monitors, cerebrospinal-fluid shunts and neuro-stimulation implants collectively anchor hospital procurement budgets, while platform upgrades, such as steerable micro-catheters, keep capital-replacement cycles brisk.Rehabilitation & wearable devices, posting a 5.18% CAGR, increasingly enable post-operative and chronic-disease monitoring at home. In-ear EEG wearables capture seizure precursors, reducing emergency admissions and widening recurring-service revenue. Competitive barriers here hinge on data-analytics IP rather than hardware, inviting tech entrants. Consequently, incumbent catheter and shunt suppliers diversify portfolios to hedge against slower growth in mature theatre-based products.
Complete Report Scope:
- By Device Type
- Neurostimulation Devices
- Interventional Neurology Devices
- Neurosurgery Devices
- Cerebrospinal Fluid Management Devices
- Neurodiagnostic & Monitoring Devices
- Neuro-rehabilitation & Wearables
- By Application
- Stroke Management
- Chronic Pain & Movement Disorders
- Epilepsy
- Neuro-degenerative Diseases
- Traumatic Brain & Spinal Injuries
- By End User
- Hospitals
- Ambulatory Surgery Centers
- Neurology Clinics
- Home-care Settings
- By Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Australia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
- North America
Geography Analysis
North America led revenue with 40.27% share in 2025 on the back of robust payer coverage, highly skilled neurologists and R&D ecosystems. Canada’s single-payer model funds nationwide closed-loop SCS trials, while Mexico accelerates MRI procurement via public-private partnerships.Asia-Pacific posts the quickest 6.92% CAGR, propelled by China’s BCI roadmap and Japan’s remote-care pilots. Government grants subsidise domestic flow-diverter manufacturing, reducing import reliance and bolstering local champions. India logs double-digit growth in detachable-coil sales as its ageing cohort expands, although affordability gaps persist.
Europe remains a steady contributor, emphasising clinical-value demonstration under Medical Device Regulation. Germany’s rising hydrocephalus incidence fuels shunt demand, whereas the United Kingdom pilots AI-triaged stroke pathways that may scale continent-wide. Meanwhile, Switzerland’s potential recognition of FDA approvals streamlines dual-market launches, benefiting US-centric manufacturers.
List of Companies Covered in this Report:
- Medtronic
- Abbott Laboratories
- Boston Scientific
- Stryker
- Johnson & Johnson (CERENOVUS)
- LivaNova
- Penumbra
- MicroPort
- Terumo
- Integra LifeSciences
- Zimmer Biomet
- Nevro
- Cochlear
- Natus Medical
- B. Braun
- Koninklijke Philips
- GE Healthcare
- Siemens Healthineers
- Neuronetics
- Inari Medical
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 Introduction
4 Market Landscape
5 Market Size & Growth Forecasts (Value, USD Billion)
6 Competitive Landscape
7 Market Opportunities & Future Outlook
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Medtronic
- Abbott Laboratories
- Boston Scientific Corp.
- Stryker Corporation
- Johnson & Johnson (CERENOVUS)
- LivaNova PLC
- Penumbra Inc.
- MicroPort Scientific
- Terumo Corporation
- Integra LifeSciences
- Zimmer Biomet
- Nevro Corporation
- Cochlear Ltd.
- Natus Medical
- B. Braun Melsungen AG
- Philips Healthcare
- GE Healthcare
- Siemens Healthineers
- Neuronetics Inc.
- Inari Medical
